Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Boronic Acids
  • Carcinoma, Transitional Cell
  • Protease Inhibitors
  • Pyrazines
  • Salvage Therapy
  • Urologic Neoplasms

abstract

  • Although bortezomib is well tolerated, it does not have antitumor activity as second-line therapy in UC.

publication date

  • May 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdm600

PubMed ID

  • 18272914

Additional Document Info

start page

  • 946

end page

  • 50

volume

  • 19

number

  • 5